Sanara MedTech (NASDAQ:SMTI) Stock Rating Lowered by Wall Street Zen

Sanara MedTech (NASDAQ:SMTI) was downgraded by stock analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report issued on Saturday.

A number of other research analysts have also recently commented on the stock. HC Wainwright cut shares of Sanara MedTech from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $36.00 to $35.00 in a report on Thursday. Zacks Research raised shares of Sanara MedTech from a “strong sell” rating to a “hold” rating in a report on Wednesday, June 10th. Freedom Capital raised shares of Sanara MedTech to a “strong-buy” rating in a report on Wednesday, June 17th. Lake Street Capital cut shares of Sanara MedTech from a “buy” rating to a “hold” rating and set a $35.00 price objective for the company. in a research report on Thursday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Sanara MedTech in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $35.00.

Sanara MedTech Stock Performance

NASDAQ:SMTI opened at $33.86 on Friday. Sanara MedTech has a twelve month low of $16.05 and a twelve month high of $35.95. The company has a quick ratio of 2.05, a current ratio of 2.28 and a debt-to-equity ratio of 6.59. The stock’s 50-day simple moving average is $24.06 and its 200 day simple moving average is $21.34. The firm has a market capitalization of $310.29 million, a PE ratio of -8.98 and a beta of 1.18.

Institutional Trading of Sanara MedTech

A number of hedge funds have recently made changes to their positions in the company. Royal Bank of Canada grew its holdings in shares of Sanara MedTech by 11.7% during the first quarter. Royal Bank of Canada now owns 131,389 shares of the company’s stock worth $2,257,000 after purchasing an additional 13,746 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Sanara MedTech by 72.0% in the first quarter. Renaissance Technologies LLC now owns 64,680 shares of the company’s stock valued at $1,111,000 after buying an additional 27,078 shares during the period. Hsbc Holdings PLC raised its holdings in Sanara MedTech by 12.1% in the 1st quarter. Hsbc Holdings PLC now owns 17,283 shares of the company’s stock valued at $301,000 after buying an additional 1,869 shares during the last quarter. Stonebridge Wealth Management LLC raised its holdings in Sanara MedTech by 1.5% in the 1st quarter. Stonebridge Wealth Management LLC now owns 136,899 shares of the company’s stock valued at $2,352,000 after buying an additional 1,965 shares during the last quarter. Finally, Rockefeller Capital Management L.P. acquired a new stake in Sanara MedTech during the 4th quarter worth approximately $299,000. 8.10% of the stock is owned by institutional investors and hedge funds.

About Sanara MedTech

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.